Investigational drugs for treating agitation in persons with dementia

References

• Ngo J, Holroyd-Leduc JM. Systematic review of recent dementia practice guidelines. Age Ageing. 2015;44:25–33.
   PubMed Web of Science ®Google Scholar
• WAR. World Alzheimer Report 2015. The global impact of dementia. Alzheimer’s Dis Int [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.alz.co.uk/research/world-report-2015
   Google Scholar
• Kelley AS, McGarry K, Gorges R, et al. The burden of health care costs for patients with dementia in the last 5 years of life. Ann Intern Med. 2015;163:729–736.
   PubMed Web of Science ®Google Scholar
• Cummings J, Mintzer J, Brodaty H, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015;27:7–17.
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Seripa D, et al. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease. Expert Opin Pharmacother. 2015;16:1–8.
   PubMed Web of Science ®Google Scholar
• Antonsdottir IM, Smith J, Keltz M, et al. Advancements in the treatment of agitation in Alzheimer’s disease. Expert Opin Pharmacother. 2015;16:1649–1656.
   PubMed Web of Science ®Google Scholar
• Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62:762–769.
   PubMed Web of Science ®Google Scholar
• Soto M, Andrieu S, Nourhashemi F, et al. Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. Int Psychogeriatr. 2015;27:181–197.
   Web of Science ®Google Scholar
• Salzman C, Jeste D, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69:889–898.
   PubMed Web of Science ®Google Scholar
• Steinberg M. Isn’t your staff trained to manage my mother? Am J Psychiatry. 2016;173:205–207.
   PubMed Web of Science ®Google Scholar
• Ballard C, Orrell M, YongZhong S, et al. Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-randomized controlled trial by the well-being and health for people with dementia (WHELD) program. Am J Psychiatry. 2016;173:252–262.
   PubMed Web of Science ®Google Scholar
• Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308:2020–2029.
   PubMed Web of Science ®Google Scholar
• Ma H, Huang Y, Cong Z, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42:915–937.
   PubMed Web of Science ®Google Scholar
• Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD003476.
   PubMedGoogle Scholar
• Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191–210.
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Turrina C, Valsecchi P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs. Drug Saf. 2010;33:273–288.
   PubMed Web of Science ®Google Scholar
• Shah A, Aftab A. Should physicians prescribe antipsychotics in dementia? Psychiatr Ann. 2016;46:97–102.
   Web of Science ®Google Scholar
• Citrome L. Atypical antipsychotics, elderly patients, and mortality risk. South Med J. 2007;100:964–965.
   PubMed Web of Science ®Google Scholar
• Garay RP, Samalin L, Hameg A, et al. Investigational drugs for anxiety in patients with schizophrenia. Expert Opin Investig Drugs. 2015;24:507–517.
   PubMed Web of Science ®Google Scholar
• Garay RP, Llorca P-M, Young AH, et al. Bipolar disorder: recent clinical trials and emerging therapies for depressive episodes and maintenance treatment. Drug Discov Today. 2014;19:1792–1800.
   PubMed Web of Science ®Google Scholar
• Garay RP, Bourin M, de Paillette E, et al. Potential serotonergic agents for the treatment of schizophrenia. Expert Opin Investig Drugs. 2015;25:1–12.
   PubMed Web of Science ®Google Scholar
• Garay RP, Citrome L, Samalin L, et al. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opin Pharmacother. 2016;17:1–16.
   PubMed Web of Science ®Google Scholar
• Holloman GH, Zeller SL. Overview of project BETA: best practices in evaluation and treatment of agitation. West J Emerg Med. 2012;13:1–2.
   PubMedGoogle Scholar
• Wilson MP, Pepper D, Currier GW, et al. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology Workgroup. West J Emerg Med. 2012;13:26–34.
   PubMedGoogle Scholar
• European Medicines Agency. Draft guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease and other dementias [Internet]. 2016 [cited 2016 Feb 29]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/02/WC500200830.pdf.
   Google Scholar
• European Medicines Agency. Human Medicines. European public assessment reports. Aripiprazole [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Food and Drug Administration. Drugs@FDA (FDA Approved Drug Products). Aripiprazole [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
   Google Scholar
• Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339–347.
   PubMed Web of Science ®Google Scholar
• De Deyn PP, Drenth AFJ, Kremer BP, et al. Aripiprazole in the treatment of Alzheimer’s disease. Expert Opin Pharmacother. 2013;14:459–474.
   PubMed Web of Science ®Google Scholar
• Citrome L, Kalsekar I, Baker RA, et al. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Curr Med Res Opin. 2014;30:1629–1641.
   PubMed Web of Science ®Google Scholar
• Rappaport SA, Marcus RN, Manos G, et al. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer’s, vascular, or mixed dementia. J Am Med Dir Assoc. 2009;10:21–27.
   PubMed Web of Science ®Google Scholar
• Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:589–604.
   PubMed Web of Science ®Google Scholar
• Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:605–614.
   PubMed Web of Science ®Google Scholar
• Citrome L, Stensbøl TB, Maeda K. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Rev Neurother. 2015;15:1219–1229.
   PubMed Web of Science ®Google Scholar
• Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Intl Clin Practice. 2015;69:978–997.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Drugs@FDA (FDA Approved Drug Products). Brexpiprazole [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
   Google Scholar
• Cipriani A, Purgato M, Furukawa TA, et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012;7:CD006534–CD.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Drugs@FDA (FDA Approved Drug Products). Celexa [Internet]. 2014 [cited 2016 Feb 29]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020822Orig1s046lbl.pdf.
   Google Scholar
• Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: The cited randomized clinical trial. JAMA. 2014;311:682–691.
   PubMed Web of Science ®Google Scholar
• Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159:460–465.
   PubMed Web of Science ®Google Scholar
• Schneider LS, Frangakis C, Drye LT, et al. Heterogeneity of treatment response to citalopram for patients with Alzheimer’s disease with aggression or agitation: the CitAD randomized clinical trial. Am J Psychiatry. 2016;173:465–472. doi:10.1176/appi.ajp.2015.15050648.
   PubMed Web of Science ®Google Scholar
• Avanir. Avanir pharmaceuticals announces initiation of phase III trial of AVP-786 for agitation in patients with Alzheimer’s disease [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.avanir.com/press/avanir-pharmaceuticals-announces-initiation-phase-iii-trial-avp-786-agitation-patients.
   Google Scholar
• Food and Drug Administration. Nabilone. Drugs@FDA [Internet]. 2006 [cited 2016 Feb 29]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
   Google Scholar
• Passmore MJ. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int J Geriatr Psychiatry. 2008;23:116–117.
   PubMed Web of Science ®Google Scholar
• Pertwee RG, Howlett AC, Abood ME, et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev. 2010;62:588–631.
   PubMed Web of Science ®Google Scholar
• Aso E, Ferrer I. Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. Front Pharmacol. 2014;5:37.
   PubMed Web of Science ®Google Scholar
• Volicer L, Stelly M, Morris J, et al. Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12:913–919.
   PubMed Web of Science ®Google Scholar
• Walther S, Mahlberg R, Eichmann U, et al. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacol (Berl). 2006;185:524–528.
   PubMed Web of Science ®Google Scholar
• van den Elsen GAH, Ahmed AIA, Verkes R-J, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. Neurology. 2015;84:2338–2346.
   PubMed Web of Science ®Google Scholar
• van den Elsen GAH, Ahmed AIA, Verkes R-J, et al. Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial. Am J Geriatr Psychiatry. 2015;23:1214–1224.
   PubMed Web of Science ®Google Scholar
• Rouru J, Wesnes K, Hanninen J, et al. Safety and efficacy of ORM-12741 on cognitive and behavioral symptoms in patients with Alzheimer’s disease: A randomized, double-blind, placebo-controlled, parallel group, multicenter, proof-of-concept 12 week study. Neurology. 2013;80:e202.
   Google Scholar
• Rinne JO, Wesnes K, Hänninen J, et al. Safety and efficacy of ORM-12741 on cognitive and behavioral symptoms in patients with Alzheimer’s disease: a randomized, double-blind, proof-of-concept study. J Neurol Sci. 2013;333:e322.
   Google Scholar
• McLaurin J, Kierstead ME, Brown ME, et al. Cyclohexanehexol inhibitors of A[beta] aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med. 2006;12:801–808.
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Keren R, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011;77:1253–1262.
   PubMed Web of Science ®Google Scholar
• Tariot P, Lyketsos C, Crans G, et al. The effects of ELND005 (Scyllo-Inositol) on emergence of neuropsychiatric symptoms (NPS) in mild/moderate Alzheimer’s disease: results from a 78-week phase 2 study (P04.215). Neurology. 2012;78( Meeting Abstracts 1):P04.215.
   Web of Science ®Google Scholar
• Lyketsos C, Abushakra S, Liang E, et al. Effects of oral ELND005 (scyllo-inositol) on neuropsychiatric symptoms in a 78-week phase 2 study in mild/moderate Alzheimer’s disease (AD): potential role of myo-inositol reduction. Alzheimer’s Dement. 2012;8:S771–S2.
   Google Scholar
• Transition. Elan and transition therapeutics announce topline summary results of phase 2 study and plans for phase 3 for ELND005 (Scyllo-inositol) [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.transitiontherapeutics.com/media/news.php.
   Google Scholar
• Olivier B, Mos J, Rasmussen D. Behavioural pharmacology of the serenic, eltoprazine. Drug Metabol Drug Interact. 1990;8:31–83.
   PubMedGoogle Scholar
• Sijbesma H, Schipper J, de Kloet ER. Eltoprazine, a drug which reduces aggressive behaviour, binds selectively to 5-HT1 receptor sites in the rat brain: an autoradiographic study. Eur J Pharmacol. 1990;177:55–66.
   PubMed Web of Science ®Google Scholar
• Amarantus. Amarantus announces positive phase 2 data for Eltoprazine in Alzheimer’s aggression [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.amarantus.com/news/press-releases/detail/2033/amarantus-announces-positive-phase-2-data-for-eltoprazine.
   Google Scholar
• Food and Drug Administration. Drugs@FDA (FDA Approved Drug Products). Citalopram hydrobromide [Internet]. 2005 [cited 2016 Feb 29]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
   Google Scholar
• Cirrito JR, Disabato BM, Restivo JL, et al. Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A. 2011;108:14968–14973.
   PubMed Web of Science ®Google Scholar
• Sheline YI, West T, Yarasheski K, et al. An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6:236re4–re4.
   PubMed Web of Science ®Google Scholar
• Kauppila T, Grönroos M, Pertovaara A. An attempt to attenuate experimental pain in humans by dextromethorphan, an NMDA receptor antagonist. Pharmacol Biochem Behav. 1995;52:641–644.
   PubMed Web of Science ®Google Scholar
• Burns JM, Boyer EW. Antitussives and substance abuse. Subst Abuse Rehabil. 2013;4:75–82.
   PubMedGoogle Scholar
• Yang LPH, Deeks ED. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect. Drugs. 2015;75:83–90.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Human Medicines. European public assessment reports. Nuedexta [Internet]. 2013 [cited 2016 Feb 29]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002560/human_med_1652.jsp&mid=WC0b01ac58001d124.
   Google Scholar
• Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314:1242–1254.
   PubMed Web of Science ®Google Scholar
• Zettl UK, Rommer P, Hipp P, et al. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord. 2016;9:9–30.
   PubMed Web of Science ®Google Scholar
• Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.
   PubMed Web of Science ®Google Scholar
• Wu C-S, Wang S-C, Gau SS-F, et al. Association of stroke with the receptor-binding profiles of antipsychotics - a case-crossover study. Biol Psychiatry. 2013;73:414–421.
   PubMed Web of Science ®Google Scholar
• Herrmann N, Lanctôt KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19:91–103.
   PubMed Web of Science ®Google Scholar
• Raivio MM, Laurila JV, Strandberg TE, et al. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry. 2007;15:416–424.
   PubMed Web of Science ®Google Scholar
• Defrancesco M, Marksteiner J, Fleischhacker WW, et al. Use of benzodiazepines in Alzheimer’s disease: a systematic review of literature. Int J Neuropsychopharmacol. 2015;18:pyv055.
   PubMed Web of Science ®Google Scholar
• Gallagher D, Herrmann N. Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy? Drugs. 2014;74:1747–1755.
   PubMed Web of Science ®Google Scholar
• Cummings J, Lai T-J, Hemrungrojn S, et al. Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer’s disease and dementia with Lewy bodies. CNS Neurosci Ther. 2016;22:159–166.
   PubMed Web of Science ®Google Scholar
• Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0123289.
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Smith JS, Keltz MA, et al. Can antidepressant medication relieve agitation in Alzheimer’s disease? Expert Rev Neurother. 2014;14:969–971.
   PubMed Web of Science ®Google Scholar
• Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;16:CD008191.
   Google Scholar
• Maher A, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359–1369.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–2314.
   PubMed Web of Science ®Google Scholar
• Aalten P, Verhey FRJ, Boziki M, et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord. 2007;24:457–463.
   PubMed Web of Science ®Google Scholar
• Aalten P, Verhey FR, Boziki M, et al. Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord. 2008;25:1–8.
   PubMed Web of Science ®Google Scholar
• Kogut C, Crouse EB, Vieweg WVR, et al. Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports. Ther Adv Drug Saf. 2013;4:189–198.
   PubMedGoogle Scholar
• Olivier B, van Oorschot R. 5-HT1B receptors and aggression: a review. Eur J Pharmacol. 2005;526:207–217.
   PubMed Web of Science ®Google Scholar
• Verhoeven WMA, Tuinier S. Serenics: anti-aggression drugs throughout history. Clin Neuropsychiatr. 2007;4:135–143.
   Google Scholar
• de Boer SF, Koolhaas JM. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. Eur J Pharmacol. 2005;526:125–139.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–864.
   PubMed Web of Science ®Google Scholar
• Fisch C, Knoebel SB. Electrocardiographic findings in sertraline depression trials. Drug Invest. 1992;4:305–312.
   Google Scholar
• ter Meulen RHJ. The ethical basis of the precautionary principle in health care decision making. Toxicol Appl Pharmacol. 2005;207:663–667.
   PubMedGoogle Scholar
• Resnik DB. The precautionary principle and medical decision making. J Med Philos. 2004;29:281–299.
   PubMed Web of Science ®Google Scholar
• Allen CL, Bayraktutan U. Risk factors for ischaemic stroke. Int J Stroke. 2008;3:105–116.
   PubMed Web of Science ®Google Scholar
• O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112–123.
   PubMed Web of Science ®Google Scholar